TFG Advisers LLC bought a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the third quarter, Holdings Channel reports. The institutional investor bought 12,399 shares of the company’s stock, valued at approximately $180,000.
A number of other institutional investors and hedge funds have also bought and sold shares of SPRY. Vanguard Group Inc. lifted its holdings in shares of ARS Pharmaceuticals by 37.0% in the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after acquiring an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC purchased a new position in ARS Pharmaceuticals in the 1st quarter worth $2,790,000. SG Americas Securities LLC lifted its stake in ARS Pharmaceuticals by 861.5% in the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares during the last quarter. GSA Capital Partners LLP boosted its position in ARS Pharmaceuticals by 11.7% during the first quarter. GSA Capital Partners LLP now owns 128,889 shares of the company’s stock valued at $1,317,000 after buying an additional 13,545 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of ARS Pharmaceuticals by 99.3% during the second quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock valued at $1,185,000 after buying an additional 69,394 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.
Insider Transactions at ARS Pharmaceuticals
In related news, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the transaction, the insider now owns 1,298,499 shares in the company, valued at $19,321,665.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the sale, the insider now directly owns 1,298,499 shares in the company, valued at $19,321,665.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Brian Dorsey sold 50,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the completion of the transaction, the chief operating officer now owns 6,024 shares of the company’s stock, valued at approximately $90,360. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,055,895 shares of company stock valued at $14,619,032. Company insiders own 40.10% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Analysis on SPRY
ARS Pharmaceuticals Stock Performance
Shares of SPRY stock opened at $16.05 on Thursday. ARS Pharmaceuticals, Inc. has a fifty-two week low of $3.38 and a fifty-two week high of $17.08. The firm has a market cap of $1.56 billion, a P/E ratio of -30.92 and a beta of 0.91. The business’s 50 day moving average price is $13.80 and its 200-day moving average price is $10.92.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $2.00 million. As a group, equities analysts predict that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Featured Articles
- Five stocks we like better than ARS Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Dividend Capture Strategy: What You Need to Know
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The How and Why of Investing in Gold Stocks
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report).
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.